5F-ADB-PINACA Wikipedia - Versionsgeschichte

ScarlettCagle66 am 4. Juni 2026 um 08:57 Uhr

2026-06-04T08:57:26Z

ScarlettCagle66 am 4. Juni 2026 um 08:47 Uhr

2026-06-04T08:47:05Z

AlizaMoberg10 am 1. Juni 2026 um 17:22 Uhr

2026-06-01T17:22:49Z

ScarlettCagle66 am 1. Juni 2026 um 17:15 Uhr

2026-06-01T17:15:07Z

ScarlettCagle66 am 1. Juni 2026 um 17:09 Uhr

2026-06-01T17:09:38Z

FranchescaWorth am 30. Mai 2026 um 18:51 Uhr

2026-05-30T18:51:43Z

CaroleHoller04 am 30. Mai 2026 um 18:46 Uhr

2026-05-30T18:46:57Z

StefanCalvin9: Die Seite wurde neu angelegt: „Such decrease remained 2 hr after the administration (Table 4). In locomotor activity, methamphetamine treated group showed approximately 4.2 times increase co…“

2026-05-26T22:05:57Z

Die Seite wurde neu angelegt: „Such decrease remained 2 hr after the administration (Table 4). In locomotor activity, methamphetamine treated group showed approximately 4.2 times increase co…“

Neue Seite

Such decrease remained 2 hr after the administration (Table 4). In locomotor activity, methamphetamine treated group showed approximately 4.2 times increase compared to the negative control treated group. Change of body weight following the treatments with JWH-081 and JWH-210 in mic LC-QTOF-MS represents a significant advancement in the field of drug detection, offering higher sensitivity, specificity, and a broader spectrum of detectable substances. Despite all negative results in the point-of-care test for recreational drugs, the liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) analysis showed that the liquid of the e-cigarette contained ADB-BUTINACA, a synthetic cannabinoid. We report a 27-year-old man who was admitted to the emergency room because of sudden 5CL ADBA powder headache, nausea, vertigo, red eyes and palpitations. Synthetic cannabinoids are gaining popularity globally and detection is not commonly availabl A 30-min period, beginning when maximal depression of locomotor activity first appeared as a function of dose, was used for analysis of dose-response data and calculation of ED50 values. During test sessions, both levers were active, such that ten consecutive responses on either lever led to [https://cannabinoidsrc4f-adb.com/ 5CL ADBA powder] reinforcement. The substitution tests occurred only if the rats had achieved 85% injection-appropriate responding on the two prior training sessions. The locomotor activity assay was used to identify approximate time courses and dose ranges of psychoactive effects, which is useful for identifying parameters for drug discrimination experiments and are also predictive of the time course of the psychoactive effects in human users. The purpose of the present study was to assess the abuse liability of 5F-MDMB-PINACA, MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA. Since there is currently no robust measure of the reinforcing/rewarding effects of cannabinoids, drug discrimination is currently the best model for assessing abuse liability of cannabinoids. The findings produce an apparent paradox, since CPP and self-administration predict with high reliability the likelihood that a compound will be abused by humans, and cannabinoids are well-known to produce active drug-seeking in human The chemical structures of the recent synthetic cannabinoids are unlike that of Δ9-THC, but are largely based on the structure of older synthetic cannabinoids that are known to have substantial abuse liability (Fig. 1 The current study indicates that the test compounds produce locomotor depression similar to that of Δ9-THC, and fully substitute for the discriminative stimulus effects of Δ9-THC. In summary, these 5F-MDMB-PINACA, MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA have similar abuse liability as Δ9-tetrahydrocannabinol and should be controlled in a similar fashion. Much of the in vivo 5CL ADBA powder testing of the synthetic cannabinoid compounds have been pre-clinical studies focused on their cannabinoid-like effects or like the present study, focused on their abuse liability. There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 (Wiley et al., 2016), and a compound from the present study, 5F-MDMB-PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016 Metabolic Profile of Synthetic Cannabinoids 5F-PB-22, PB-22, XLR-11 and UR-144 by Cunninghamella elegans This might be due to the low activity of numerous metabolizing enzymes resulting in lower drug biotransformation . HepG2 model detected the major ester hydrolysis metabolite of 4F-MDMB-BINACA in abundance but the rest of the metabolites were found in a small amount. Elegans and HLM models detected all of the in-vivo metabolites (100%), whilst HepG2 cells detected 7 out of the 8 in-vivo metabolites (87.5%). Hence, structural elucidation could not be confirmed unless a reference standard is made availabl 4. Drugs Short-onset, short-acting compounds have a greater abuse liability, and long-acting compounds pose problems of long-acting adverse effects and interactions with other drugs. The duration of action of the synthetic cannabinoids tested using the 8-h protocol have varied widely, with some producing a duration of action no longer than 1 h, others producing a duration of action between 1–2 h, and others lasting more than 2 h. There seems to be a trend of newer synthetic cannabinoids being more potent than earlier compounds. All of the compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al., 2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were observed between 0–30 min. Michael B Gat

← Nächstältere Version		Version vom 4. Juni 2026, 08:57 Uhr
Zeile 1:		Zeile 1:
−	~~Tremors were not observed following AMB~~-~~FUBINACA during~~ the ~~drug discrimination study~~, ~~but the maximum dose tested~~ was ~~only 0~~.~~1 mg~~/kg, ~~which is 10~~-~~fold lower than the dose that produced tremors in the mic~~<br><br>~~<br>Thirty minutes prior to the training sessions, rats received an injection of either vehicle or Δ9~~-~~THC and were subsequently placed in~~ the ~~behavior~~-~~testing chambers, where food (45~~-~~mg food pellets; Bio-Serve, Frenchtown, NJ) was available as a reinforcer for every ten responses~~ (~~FR10~~) on ~~a designated injection appropriate lever. A houselight was centered over~~ the ~~hopper close to~~ the ~~ceiling~~ and was ~~illuminated only when~~ the ~~levers were active~~. ~~Each dose range included doses that were without effect to those producing~~ at ~~least 50% depression compared to vehicle control~~. ~~Twenty~~-~~four male Sprague~~-~~Dawley rats~~ were ~~obtained from Envigo~~ (~~Houston, TX~~)~~. 5CLADBA Male ND4 Swiss–Webster mice were obtained from Envigo~~ (~~Houston~~, ~~TX) at approximately 8 weeks~~ of ~~age and maintained in~~ the ~~University of North Texas Health Science Center~~ (~~UNTHSC~~) ~~animal facility for two weeks prior to testin~~<br>~~<br>4~~. ~~Drugs~~ <br>~~In general,~~ the ~~locomotor depressant~~ and ~~discriminative stimulus effects~~ have been ~~observed at doses that do not produce adverse effects~~, ~~although tremors were observed upon handling in mice that received JWH-210~~ (~~Gatch et al~~., ~~2016~~), and 5F-~~AMB produced sustained vocalization and convulsions~~ in ~~rats~~ (~~Gatch et al~~., ~~2018). All~~ of the ~~synthetic cannabinoids tested in~~ the ~~present study fully substituted for the discriminative stimulus effects~~ of Δ9-~~THC~~. ~~Subsequently~~, ~~a one-way analysis of variance was conducted on horizontal activity counts for~~ the ~~30-min period of maximal effect, and planned comparisons were conducted for each~~ dose ~~against the vehicle control using single degree-~~of-~~freedom F tests. A two~~-~~way analysis of variance~~, ~~with dose as a~~ between ~~groups factor~~ and ~~time as a within subject factor~~, was ~~conducted on horizontal activity counts~~/~~10 min interval~~. ~~Locomotor activity~~ in ~~mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times~~ of ~~peak effect. Previous studies~~ have ~~demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act~~ at ~~the CB1 receptor.~~<br>~~Michael B Gatch~~ <br>~~Substantial depressant effects were observed within~~ the ~~first~~ 10 min, and ~~maximal depression was observed between 0–30 min following administration~~. ~~Tremors were observed 30 minutes following~~ 1 mg/kg ~~AMB-FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects~~ were observed within ~~the first~~ 10 min, and ~~maximal depression was~~ observed between ~~10–40~~ min ~~and lasted up to 2~~.~~5 to 3 h at~~ the ~~5CLADBA highest~~ dose ~~tested (~~0.5 mg/kg).<br>~~Figure 1.~~ <br>~~There is indication that at least some of the first~~-~~generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2~~ (~~Wiley et al., 2016~~)~~, and a compound from the present study, 5F-MDMB-PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons~~ (~~Asaoka et al., 2016~~)~~. As previously mentioned, all of the compounds tested~~ in ~~the present study (MDMB-PINACA, MDMB-CHMICA, MDMB-FUBINACA, ADB-FUBINACA,~~ and ~~AMB-FUBINACA) act as agonists at CB1 receptors (Banister et al.~~, ~~2015, 2016; Gamage et al., 2018), which suggests these compounds will produce Δ9-THC-like effects, including abuse liability. Tremors were not observed following AMB-FUBINACA during~~ the ~~drug discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors in the mic~~<br><br><br>~~The % peak area abundance ratio of metabolites detected in the urine samples are often affected by numerous factors~~ such as ~~drug intake behaviour (intake route, amount~~ of ~~drug and intake frequency)~~, ~~time from last drug intake and metabolic stability~~. ~~This indicated that the phase I metabolism~~ of 4F-~~MDMB-BINACA are unlikely to be affected significantly by polydrug intake. Oxidative defluorination with subsequent butanoic acid formation~~ (~~B17~~) ~~metabolite,~~ the ~~second major metabolite after monohydroxylation in~~ the C. ~~Ester hydrolysis with dehydrogenation formed in~~-~~vivo in this study was also reported among other indazole carboxamide type SCBs with tert-leucine methyl ester moieties such as 5F-MDMB-PINACA~~ and ~~MDMB~~-~~4en-PINACA [39, 40]~~. ~~Similar to the in~~-~~vivo findings~~, ~~4F-MDMB-BINACA ester hydrolysis (B22) was the major metabolite for both HepG2 and HLM models~~, ~~consistent with the known hydrolytic activity~~ of ~~CES reported<br>~~<br><br>~~Demographic and clinical features are recorded and blood and/or urine samples analysed using high-resolution accurate mass liquid chromatography-mass spectrometry.~~ The ~~authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence~~ the ~~work reported in this paper. Second~~, ~~we could not~~ [https://cannabinoidsrc4f-adb.com/ 5CLADBA] ~~retrieve further detailed information about~~ the e-~~cigarette that was~~ used by the patient ~~such as~~ the ~~label or~~ the ~~region~~ of ~~origin. Whether a~~ recreational drug ~~can be administered via vaping~~, ~~depends on whether~~ the ~~drug becomes volatile under the evaporation temperature~~ of the e-cigarette. ~~Of these samples, 22 contained one or more SCRAs, THC was only detected in 11 samples, only one contained cannabidiol and 6 contained~~ a ~~mixture of THC~~ and ~~cannabidiol. There is difficulty in finding~~ the ~~right information about~~ the ~~NPS, defining their potency~~ and ~~confirmation of their existence in e-liquids or urine samples.<br>Data availabili~~	+	Due to the unknown toxicity of newly emerging SCRAs, forensic assessments of cases involving these substances are challenging. According to the reported cases and reviews of the scientific literature, concurrent ethanol consumption should amplify the toxicity of SCRAs. The concentration of 4F-MDMB-BINACA in the postmortem blood was 2.50 and 2.34 ng/mL, and blood alcohol concentration was 2.11 and 2.49 g/L, respectively. Two fatal cases are reported caused by simultaneous consumption of 4F-MDMB-BINACA and ethanol.<br>Fig. 2. <br>4F-MDMB-BINACA was hydrolysed via ester hydrolysis forming the 4F-MDMB-BINACA ester hydrolysis metabolite (B22). Data obtained from the twenty urine samples were retrospectively analysed and processed using TraceFinder software based on the identification criteria of mass errors less than ± 5 ppm for full MS peaks and MS/MS peaks from the theoretical mass and matching of MS/MS spectra. The mixture was vortex-mixed and 500 µL of this mixture and 500 µL of methanol were loaded onto the Clean Screen FASt® tube. After incubation, the mixture was cooled at room temperature, and 150 µL of purified water was added. High-resolution QTOF-MS data were acquired on an Agilent 6510 Accurate Mass QTOF mass spectrometer (Agilent Technologies) equipped with dual electrospray ionization (ESI) source operated in both positive and negative ion modes, to determine accurate masses of the metabolites. Chromatographic separation was performed on an Agilent 1290 LC system with a Poroshell 120 EC-C18 analytical column (2.7 μm, 75 × 2.1 mm; Agilent Technologies, Santa Clara, CA, USA).<br>Fig. 1. <br>This outcome was anticipated since CES-mediated hydrolysis is commonly 5CLADBA reported as the major metabolic pathway among the SCBs impacting the terminal ester group . Glucosides and sulfate metabolites have been reported with other SCBs where C. From these three samples, sample 2 contained only an ester hydrolysis metabolite (m/z 350). Both ester hydrolysis followed by oxidative defluorination to butanoic acid (B4, m/z 362) and monohydroxylation at tert-leucine moiety (B8, m/z 366) metabolites were found in 16/20 urine samples (Table 2). A In-vitro metabolites observed in common among respective seven most abundant metabolites in b C. The product ion detected at m/z 235, indicating loss of sulfate, confirmed the identity of the sulfation metabolite.<br>Fungus C. elegans <br>Concentrations of 4F-MDMB-BINACA in the postmortem blood samples were 2.50 and 2.34 ng/mL, which are in line with published data. Although the lethal dose of 4F-MDMB-BINACA is unknown, its concentration in postmortem blood samples was found to range between 0.10 and 2.90 ng/mL . In SCRA-related cases in which the deceased suffered from heart disease, the SCRA concentration in the postmortem blood was less than 1 ng/mL . Concentrations of SCRAs in postmortem cases cover a wide range ; however, some reports of survival have also been published—even at relatively high blood SCRA concentrations [19, 20<br><br><br>All of the compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al., 2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were 5CLADBA observed between 0–30 min. Duration of the locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2.5 h following 1 mg/k<br><br> High-resolution QTOF-MS data were acquired on an Agilent 6510 Accurate Mass QTOF mass spectrometer (Agilent Technologies) equipped with dual electrospray ionization (ESI) source operated in both positive and negative ion modes, to determine accurate masses of the metabolite<br><br><br>High resolution mass spectrometry such as LC-QTOF-MS allows the detection and identification of a broad spectrum of recreational drugs, including new psychoactive substances. A point-of-care drugs of abuse (DOA) test was initially performed on the urine of the patient. He confirmed drinking 750 ml energy drink without any further consumption of food and using an e-cigarette from Gaziantep, Turkey 10 seconds before the onset of his first symptoms. He usually smokes a pack of cigarettes a day and sometimes smokes e-cigarettes. Combined with non-specific, transient symptoms, clinical recognition of SCRA intoxication is challenging .<br> Data availability <br>The intensity is plotted against the retention time for both chromatograms, demonstrating the [https://cannabinoidsrc4f-adb.com/ 5CLADBA] presence and elution profiles of nicotine and ADB-BUTINACA in the analysed vape liquid sample. LC-QTOF-MS Chromatograms of Nicotine (Top) and ADB-BUTINACA (Bottom) in the Vape Liquid used by the patient. The LC-QTOF-MS analysis showed that the e-liquid contained nicotine and ADB-BUTINACA (Fig. 1). Because the point-of-care DOA test is generally not able to detect synthetic recreational drug substances, the liquid of the e-cigarette was thereafter screened using liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) on the Waters™ Xevo G3 QTOF MS system. After eating a light meal and drinking caffeinated sports drinks at the ER, the nausea complaints of the patient were reduced and the patient was discharged hom

← Nächstältere Version		Version vom 4. Juni 2026, 08:47 Uhr
Zeile 1:		Zeile 1:
−	~~These synthetic cannabinoids act [https://cannabinoidsrc4f~~-~~adb~~.~~com~~/ ~~adb butinaca] directly at cannabinoid CB1~~ and ~~CB2 receptors~~ as ~~does Δ9~~-~~tetrahydrocannabinol~~ (~~Δ9-THC~~) ~~found~~ in ~~marijuana~~, ~~but~~ have ~~different chemical structures unrelated to Δ9~~-~~THC~~, ~~different metabolism~~, and ~~often greater toxicity~~ (~~Fantegrossi~~ et al., ~~2014~~). ~~Discriminative~~ stimulus effects were tested ~~in rats trained~~ to ~~discriminate Δ9~~-~~tetrahydrocannabinol~~ (3 mg/kg, ~~30-min pretreatment~~). 5F-MDMB-PINACA (~~also known as 5F-ADB~~, ~~5F-ADB~~-PINACA), MDMB-~~CHIMICA~~, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA (~~also known as FUB~~-AMB, ~~MMB~~-~~FUBINACA~~) ~~were tested for~~ in vivo ~~cannabinoid~~-~~like effects~~ to ~~assess their abuse liabilit~~<br><br><br>Demographic and clinical features are recorded and blood and/or urine samples analysed using high-resolution accurate mass liquid chromatography-mass spectrometry. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Second, we could not adb ~~butinaca~~ retrieve further detailed information about the e-cigarette that was used by the patient such as the label or the region of origin. Whether a recreational drug can be administered via vaping, depends on whether the drug becomes volatile under the evaporation temperature of the e-cigarette. Of these samples, 22 contained one or more SCRAs, THC was only detected in 11 samples, only one contained cannabidiol and 6 contained a mixture of THC and cannabidiol. There is difficulty in finding the right information about the NPS, defining their potency and confirmation of their existence in e-liquids or urine samples.<br>Data availabili<br><br><br>As synthetic cannabinoid receptor agonists (SCRA) are gaining popularity globally, clinicians have to understand that intoxication caused by vaping SCRA is not detected by commonly available tests. He confirmed that he had been vaping an electronic cigarette (e-cigarette) earlier that day just before the onset of his symptoms. Metabolic acidosis (1/3, 0/7) and respiratory acidosis (1/3, 0/7), All 10 patients recovered with supportive care, including intubation and ventilation for one case. In 3 cases ADB-BUTINACA was the only substance detected, while in seven other substances of misuse were also detected including other SCRA, opioids, benzodiazepines cocaine and pregabali<br><br><br>§ (3) of the Hungarian act of Forensic Experts (2016.XXIX), the data of the reported case can be utilized freely for scientific and educational purposes without special ethical permission. These results indicate that the simultaneous intoxication of SCRA and ethanol directly and exclusively caused the death of the two victims. The victims did not have any significant diseases that could have contributed to the outcome. Very limited data are available in the scientific literature about the possible effects of the combined consumption of SCRAs and ethanol. Several case reports describe that the presence of a little ng/mL (0.37–4.1) of SCRAs and a high—but not lethal—concentration of ethanol (1.45–2.7 g/L) directly and exclusively contributed to the death of the victim [24–27] (Table 2). The fact that 4F-MDMB-BINACA was not detected in postmortem urine samples is partly explained by the high rate of hepatic metabolism of SCRAs [11, 14, 22], but also suggests that the victims consumed 4F-MDMB-BINACA shortly before their death<br><br>Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors in the mic<br><br>4. Drugs <br>Short-onset, short-acting compounds have a greater abuse liability, and long-acting compounds pose problems of long-acting adverse effects and interactions with other drugs. The duration of action of the synthetic cannabinoids tested using the 8-h protocol have varied widely, with some producing a duration of action no longer than 1 h, others producing a duration of action between 1–2 h, and others lasting more than 2 h. There seems to be a trend of newer synthetic cannabinoids being more potent than earlier compounds. All of the compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al., 2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were observed between 0–30 min.<br>Michael B Gat<br><br>Legal status <br>JWH-210 Chemical Powder offers a reliable solution for laboratories seeking a compound that meets stringent requirements. Researchers often require compounds that are consistent and dependable, and this product delivers on both fronts. Whether used in small-scale experiments or larger research projects, the compound maintains its integrity under recommended storage conditions. This ensures ease of handling and precise measurement during laboratory use. Each batch undergoes detailed verification to ensure purity, consistency, and accuracy, making it suitable for controlled experimental environments. This study was supported by a grant (13181MFDS654) of the National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Republic of Kore	+	Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors in the mic<br><br><br>Thirty minutes prior to the training sessions, rats received an injection of either vehicle or Δ9-THC and were subsequently placed in the behavior-testing chambers, where food (45-mg food pellets; Bio-Serve, Frenchtown, NJ) was available as a reinforcer for every ten responses (FR10) on a designated injection appropriate lever. A houselight was centered over the hopper close to the ceiling and was illuminated only when the levers were active. Each dose range included doses that were without effect to those producing at least 50% depression compared to vehicle control. Twenty-four male Sprague-Dawley rats were obtained from Envigo (Houston, TX). 5CLADBA Male ND4 Swiss–Webster mice were obtained from Envigo (Houston, TX) at approximately 8 weeks of age and maintained in the University of North Texas Health Science Center (UNTHSC) animal facility for two weeks prior to testin<br><br>4. Drugs <br>In general, the locomotor depressant and discriminative stimulus effects have been observed at doses that do not produce adverse effects, although tremors were observed upon handling in mice that received JWH-210 (Gatch et al., 2016), and 5F-AMB produced sustained vocalization and convulsions in rats (Gatch et al., 2018). All of the synthetic cannabinoids tested in the present study fully substituted for the discriminative stimulus effects of Δ9-THC. Subsequently, a one-way analysis of variance was conducted on horizontal activity counts for the 30-min period of maximal effect, and planned comparisons were conducted for each dose against the vehicle control using single degree-of-freedom F tests. A two-way analysis of variance, with dose as a between groups factor and time as a within subject factor, was conducted on horizontal activity counts/10 min interval. Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at the CB1 receptor.<br>Michael B Gatch <br>Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at the 5CLADBA highest dose tested (0.5 mg/kg).<br>Figure 1. <br>There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 (Wiley et al., 2016), and a compound from the present study, 5F-MDMB-PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016). As previously mentioned, all of the compounds tested in the present study (MDMB-PINACA, MDMB-CHMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA) act as agonists at CB1 receptors (Banister et al., 2015, 2016; Gamage et al., 2018), which suggests these compounds will produce Δ9-THC-like effects, including abuse liability. Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors in the mic<br><br><br>The % peak area abundance ratio of metabolites detected in the urine samples are often affected by numerous factors such as drug intake behaviour (intake route, amount of drug and intake frequency), time from last drug intake and metabolic stability. This indicated that the phase I metabolism of 4F-MDMB-BINACA are unlikely to be affected significantly by polydrug intake. Oxidative defluorination with subsequent butanoic acid formation (B17) metabolite, the second major metabolite after monohydroxylation in the C. Ester hydrolysis with dehydrogenation formed in-vivo in this study was also reported among other indazole carboxamide type SCBs with tert-leucine methyl ester moieties such as 5F-MDMB-PINACA and MDMB-4en-PINACA [39, 40]. Similar to the in-vivo findings, 4F-MDMB-BINACA ester hydrolysis (B22) was the major metabolite for both HepG2 and HLM models, consistent with the known hydrolytic activity of CES reported<br><br><br>Demographic and clinical features are recorded and blood and/or urine samples analysed using high-resolution accurate mass liquid chromatography-mass spectrometry. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Second, we could not [https://cannabinoidsrc4f-adb.com/ 5CLADBA] retrieve further detailed information about the e-cigarette that was used by the patient such as the label or the region of origin. Whether a recreational drug can be administered via vaping, depends on whether the drug becomes volatile under the evaporation temperature of the e-cigarette. Of these samples, 22 contained one or more SCRAs, THC was only detected in 11 samples, only one contained cannabidiol and 6 contained a mixture of THC and cannabidiol. There is difficulty in finding the right information about the NPS, defining their potency and confirmation of their existence in e-liquids or urine samples.<br>Data availabili

← Nächstältere Version		Version vom 1. Juni 2026, 17:22 Uhr
Zeile 1:		Zeile 1:
−	~~Figure 1~~. ~~<br>Each training session lasted a maximum of 10 min,~~ and ~~the rats could earn up to 20 food pellets. Thirty minutes prior to the training sessions, rats received an injection of either vehicle or~~ Δ9-THC ~~and were subsequently placed~~ in ~~the behavior-testing chambers~~, ~~where food (45~~-~~mg food pellets; Bio-Serve~~, ~~Frenchtown~~, ~~NJ) was available as a reinforcer for every ten responses~~ (~~FR10~~) ~~on a designated injection appropriate lever~~. ~~A houselight was centered over the hopper close to the ceiling and was illuminated only when the levers~~ were ~~active. Each dose range included doses that were without effect~~ to ~~those producing at least 50% depression compared to vehicle control. Twenty-four male Sprague~~-~~Dawley rats were obtained from Envigo~~ (~~Houston~~, TX). ~~Male ND4 Swiss–Webster mice were obtained from Envigo~~ (~~Houston~~, TX) ~~at approximately 8 weeks of age~~ and ~~maintained in the University of North Texas Health Science Center~~ (~~UNTHSC~~) ~~animal facility~~ for ~~two weeks prior~~ to ~~testin~~<br><br><br>~~Product ions detected at m~~/~~z 302, 217, and 145 (B2) confirmed~~ that ~~tert-leucine and indazole moieties remained unchanged~~, ~~leading to~~ the ~~structure elucidation of a hydroxy~~-~~functional group at~~ the ~~4-position of~~ the ~~butyl side chain by oxidative defluorination. The product ion m/z 336 (loss of methyl ester moiety) further confirmed~~ the ~~presence~~ of ~~dihydroxylated metabolites~~. ~~The precursor ion~~, ~~m/z 364 (B14, B5/B6) had a loss of 2 Da from m/z 366 indicated further dehydrogenation~~ of the ~~ester hydrolysis plus monohydroxylated metabolites~~. ~~The presence of the product ion m/z 320~~, ~~likely formed from a loss of carbon dioxide~~, ~~indicated monohydroxylation at the tert-leucine~~ in ~~B8 (m/z 219)~~, ~~butyl side chain in B9 (m/z 145)~~ and ~~indazole moiety in B13 (m/z 161). The precursor ion, m/z 350 showed~~ a ~~loss~~ of ~~14 Da explaining~~ the ~~hydrolysis~~ of ~~methyl ester from 4F~~-~~MDMB-BINACA~~.<br>~~Fig. 2.~~ <br>~~The precursor ion m/z 396~~ (~~B10, B12/B15~~) ~~was 32 Da higher than the parent drug~~, 4F-~~MDMB-BINACA, suggesting~~ the ~~addition~~ of ~~two hydroxy groups~~. ~~All the below explanations for transformations into metabolites are based on the data shown in Fig. Metabolites were identified according to their precursor ions, product ions~~, and ~~fragmentation patterns~~ (~~Fig.~~ 1). ~~Traditional in~~-~~vivo metabolism studies to generate human metabolites of drugs relied heavily on~~ the ~~use of whole animal model systems, which are expensive~~, ~~limited by drug administration amount, influenced by species variation and faced by many ethical issues. Eight~~ in~~-vivo metabolites tentatively identified~~ were ~~mainly products of ester hydrolysis with or without additional dehydrogenation~~, ~~N-dealkylation~~, ~~monohydroxylation~~ and ~~oxidative defluorination with further oxidation to butanoic acid.~~<br>~~Fig. 1.~~ <br>~~Monitoring metabolism~~ of ~~synthetic cannabinoid 4F-MDMB-BINACA via high-resolution mass spectrometry assessed in cultured hepatoma cell line~~, ~~fungus, 5CLADBA liver microsomes~~ and ~~confirmed using urine samples~~ The ~~threshold for fatal overdose~~ of combined ~~use~~ of SCRAs and ethanol ~~can be estimated as~~ a little ng/mL (0.37–4.1 ~~ng/mL according to the reported cases~~) of ~~SCRA~~ and 1.~~5–2~~.5 g/L ~~of ethanol. The reported cases~~ and ~~reviews~~ of the ~~scientific literature suggest a possible synergistic effect between SCRAs and ethanol, because their combined use clearly increases their toxicity~~. The ~~victim died due to severe necrotizing pancreatitis and acute kidney injury evolving into multi~~-~~organ failure~~ 11 ~~days after hospital admission . Studies have found no unequivocal synergistic effect between THC and ethanol at low or moderate ethanol doses [29~~, 30], but ~~no data on high doses of ethanol are available. Given~~ that ~~THC and ethanol act on~~ the ~~same receptors, data on~~ their ~~simultaneous use may yield important insights in this regard.~~<br>~~Fungus C. elegans~~ <br>~~Concentrations of 4F~~-~~MDMB-BINACA in~~ the ~~postmortem blood samples were 2.50 and 2.34 ng/mL~~, ~~which are in line with published data. Although~~ the ~~lethal~~ dose ~~of 4F-MDMB-BINACA is unknown, its concentration in postmortem blood samples~~ was ~~found to range between~~ 0.10 ~~and 2.90 ng/mL . In SCRA~~-~~related cases in which~~ the ~~deceased suffered from heart disease, the SCRA concentration~~ in the postmortem blood was less than 1 ng/mL . Concentrations of SCRAs in postmortem cases cover a wide range ; however, some reports of survival have also been published—even at relatively high blood SCRA concentrations [19, 20<br><br><br>All of the compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al., 2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were ~~[https://cannabinoidsrc4f-adb.com/ 5CLADBA]~~ observed between 0–30 min. ~~Duration of the locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2.5 h following 1 mg/k~~<br><br>5F-~~MDMB~~-~~PINACA (also known as 5F-ADB~~, ~~5F-ADB-PINACA)~~, ~~MDMB-CHIMICA~~, ~~MDMB-FUBINACA~~, ~~ADB-FUBINACA~~, and ~~AMB-FUBINACA (also known as FUB-AMB~~, ~~MMB-FUBINACA) were tested for in vivo cannabinoid-like effects to assess their abuse liabilit~~	+	These synthetic cannabinoids act [https://cannabinoidsrc4f-adb.com/ adb butinaca] directly at cannabinoid CB1 and CB2 receptors as does Δ9-tetrahydrocannabinol (Δ9-THC) found in marijuana, but have different chemical structures unrelated to Δ9-THC, different metabolism, and often greater toxicity (Fantegrossi et al., 2014). Discriminative stimulus effects were tested in rats trained to discriminate Δ9-tetrahydrocannabinol (3 mg/kg, 30-min pretreatment). 5F-MDMB-PINACA (also known as 5F-ADB, 5F-ADB-PINACA), MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA (also known as FUB-AMB, MMB-FUBINACA) were tested for in vivo cannabinoid-like effects to assess their abuse liabilit<br><br><br>Demographic and clinical features are recorded and blood and/or urine samples analysed using high-resolution accurate mass liquid chromatography-mass spectrometry. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Second, we could not adb butinaca retrieve further detailed information about the e-cigarette that was used by the patient such as the label or the region of origin. Whether a recreational drug can be administered via vaping, depends on whether the drug becomes volatile under the evaporation temperature of the e-cigarette. Of these samples, 22 contained one or more SCRAs, THC was only detected in 11 samples, only one contained cannabidiol and 6 contained a mixture of THC and cannabidiol. There is difficulty in finding the right information about the NPS, defining their potency and confirmation of their existence in e-liquids or urine samples.<br>Data availabili<br><br><br>As synthetic cannabinoid receptor agonists (SCRA) are gaining popularity globally, clinicians have to understand that intoxication caused by vaping SCRA is not detected by commonly available tests. He confirmed that he had been vaping an electronic cigarette (e-cigarette) earlier that day just before the onset of his symptoms. Metabolic acidosis (1/3, 0/7) and respiratory acidosis (1/3, 0/7), All 10 patients recovered with supportive care, including intubation and ventilation for one case. In 3 cases ADB-BUTINACA was the only substance detected, while in seven other substances of misuse were also detected including other SCRA, opioids, benzodiazepines cocaine and pregabali<br><br><br>§ (3) of the Hungarian act of Forensic Experts (2016.XXIX), the data of the reported case can be utilized freely for scientific and educational purposes without special ethical permission. These results indicate that the simultaneous intoxication of SCRA and ethanol directly and exclusively caused the death of the two victims. The victims did not have any significant diseases that could have contributed to the outcome. Very limited data are available in the scientific literature about the possible effects of the combined consumption of SCRAs and ethanol. Several case reports describe that the presence of a little ng/mL (0.37–4.1) of SCRAs and a high—but not lethal—concentration of ethanol (1.45–2.7 g/L) directly and exclusively contributed to the death of the victim [24–27] (Table 2). The fact that 4F-MDMB-BINACA was not detected in postmortem urine samples is partly explained by the high rate of hepatic metabolism of SCRAs [11, 14, 22], but also suggests that the victims consumed 4F-MDMB-BINACA shortly before their death<br><br>Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors in the mic<br><br>4. Drugs <br>Short-onset, short-acting compounds have a greater abuse liability, and long-acting compounds pose problems of long-acting adverse effects and interactions with other drugs. The duration of action of the synthetic cannabinoids tested using the 8-h protocol have varied widely, with some producing a duration of action no longer than 1 h, others producing a duration of action between 1–2 h, and others lasting more than 2 h. There seems to be a trend of newer synthetic cannabinoids being more potent than earlier compounds. All of the compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al., 2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were observed between 0–30 min.<br>Michael B Gat<br><br>Legal status <br>JWH-210 Chemical Powder offers a reliable solution for laboratories seeking a compound that meets stringent requirements. Researchers often require compounds that are consistent and dependable, and this product delivers on both fronts. Whether used in small-scale experiments or larger research projects, the compound maintains its integrity under recommended storage conditions. This ensures ease of handling and precise measurement during laboratory use. Each batch undergoes detailed verification to ensure purity, consistency, and accuracy, making it suitable for controlled experimental environments. This study was supported by a grant (13181MFDS654) of the National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Republic of Kore

← Nächstältere Version		Version vom 1. Juni 2026, 17:15 Uhr
Zeile 1:		Zeile 1:
−	~~All~~ of the ~~compounds tested~~ in the ~~present study depressed locomotor activity as is typical for other synthetic cannabinoids~~ (~~see review by Wiley et al.~~, ~~2017~~)~~. Average horizontal activity counts/10 min~~ as a ~~function of time~~ (~~10 min bins~~) ~~and dose~~. ~~Depressant effects of 1.33 mg/kg were observed within 10 min following administration~~ and ~~peak depressant effects~~ were ~~click through the next webpage observed between 0–30 min~~. ~~Duration of the locomotor~~ depression ~~increased over dose~~ from ~~30 min following 0~~.~~1 mg/kg to 2.5 h following 1 mg/k<br><br>One recent study has looked~~ at ~~other mechanisms~~ of ~~action~~ in ~~some of~~ the ~~older synthetic cannabinoids and reported that some produced varying amounts~~ of ~~activity at sites which are related~~ to ~~cardiotoxicity and heart disease (Wiley et al., 2016~~<br><br><br>~~Although there were reports on the metabolism of 4F-MDMB-BINACA using in~~-~~vivo~~ and ~~various in-vitro models~~, ~~studies were either conducted using small in~~-~~vivo sample size such as 1 to~~ 4 samples [5, 29] or in closed environments such as forensic psychiatric wards and prisons . The hepatic cell line HepG2 is often used as an initial screen as it is known to produce high reproducibility results with relatively stable enzyme concentration, although they are limited by the low-~~level expression~~ of ~~several metabolizing enzymes, including~~ the ~~cytochrome P450~~ (~~CYP~~) ~~class~~ of ~~proteins [17, 18]~~. ~~In-vitro metabolism studies are generally used to complement these data using perfused organs~~, ~~tissue or cell cultures and microsomal preparations amongst which pooled human liver microsomes~~ (~~HLM~~) ~~have been frequently used to elucidate metabolism~~ of ~~SCBs [12,13,14,15,16]. Since most SCBs are found extensively in metabolized forms in urine,~~ the ~~identification of~~ metabolites ~~is of vital importance for forensic and clinical toxicologists. Identifying SCB intake and its correlating specific adverse effects require rapid elucidation of these SCBs~~. The ~~proliferation~~ of ~~SCBs has become~~ a ~~global challenge as new compounds are rapidly introduced into the illegal drug market to evade existing drug law<br><br>In general~~, the ~~locomotor depressant and discriminative stimulus effects have been observed at doses that do not produce adverse effects~~, ~~although tremors were observed upon handling~~ in ~~mice that received JWH-210~~ (~~Gatch et al., 2016~~), and ~~5F-AMB produced sustained vocalization and convulsions~~ in ~~rats~~ (~~Gatch et al., 2018<br><br><br>Taken together these data further confirmed the structure elucidation of B16~~. The precursor ion m/z ~~276 (B1) detected, which was 74~~ Da ~~lower than that for~~ the 4F-MDMB-BINACA ~~ester hydrolysis metabolite (B22), indicated N-dealkylation of B22~~. The precursor ion m/z ~~348 and product ion detected at m~~/~~z 217 (B2~~) ~~identified~~ was 2 Da ~~less~~ than the 4F-MDMB-BINACA ~~ester hydrolysis metabolite (B22)~~, ~~indicating oxidative defluorination (loss of fluorine with~~ addition of hydroxy ~~[https://cannabinoidsrc4f-adb~~.~~com/ click through the next webpage] group<br><br><br>The same procedure was then applied to~~ the ~~mice once every day~~ for ~~5 days. It was considered as coordination disturbance when mice fell from~~ the ~~test apparatus within 2 min~~. ~~Mice that remained~~ their ~~position~~ on the ~~running apparatus at 10 rpm for at least 2 min~~ were ~~selected for~~ further ~~evaluation~~.<br>~~Table of Conten~~<br>~~<br><br>When clinical presentation and/or initial DOA testing results are inconclusive, additional testing with LC~~-~~QTOF~~-MS can be ~~valuable~~ and ~~is recommended~~. SCRAs and ~~other NPS may not be detected by point~~-~~of-care DOA tests~~. ~~In this case~~, ~~the point-~~of~~-care DOA urine screening was not able to detect~~ the ~~synthetic cannabinoid ADB-BUTINAC~~<br><br>~~<br>Similarly, precursor ion identified at m/z 380 (B19/B21, B23/B25) was 16 Da higher than the~~ 4F-MDMB-BINACA~~, indicating monohydroxylation at~~ the ~~butyl side chain (B19/B21)~~ and ~~indazole (B23/B25) moieties with product ions m/z 145 and 161, respectively~~. ~~Metabolites identified at m~~/~~z 366 (B8, B9, B13)~~, which ~~was 16 Da higher than~~ the 4F-MDMB-BINACA ~~ester hydrolysis metabolite (B22)~~, ~~confirmed monohydroxylation upon ester hydrolysis~~. ~~Death involving these drugs have been reported [5,6,7,8,9],~~ and ~~this raises public health and social concerns~~. ~~Due to their similar physiological effects to~~ the ~~principal psychoactive component of cannabis~~, ~~Δ9-tetrahydrocannabinol (THC), SCBs are gaining popularity and are often abused as recreational drugs. The fact that similar 4F-MDMB-BINACA and ethanol concentrations were detected~~ in the postmortem blood ~~samples~~ of ~~both victims suggests that both substances played~~ a ~~role in the fatal outcom~~<br><br>~~4. Drugs~~ <br>In general, the locomotor depressant and discriminative stimulus effects have been observed at doses that do not produce adverse effects, although tremors were observed upon handling in mice that received JWH-210 (Gatch et al., 2016), and 5F-AMB produced sustained vocalization and convulsions in rats (Gatch et al., 2018). All of the ~~synthetic cannabinoids~~ tested in the present study ~~fully substituted~~ for ~~the discriminative stimulus effects of Δ9-THC~~. ~~Subsequently~~, ~~a one-way analysis of variance was conducted on~~ horizontal activity counts ~~for the 30-~~min ~~period of maximal effect, and planned comparisons were conducted for each dose against the vehicle control using single degree-of-freedom F tests. A two-way analysis of variance, with dose~~ as a ~~between groups factor and~~ time ~~as a within subject factor, was conducted on horizontal activity counts/~~10 min ~~interval~~. ~~Locomotor activity in mice was tested to screen for locomotor depressant~~ effects ~~and to identify behaviorally-active dose ranges and times~~ of ~~peak effect~~. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at the CB1 receptor.<br>Michael B Gatch <br>Substantial depressant effects were observed within ~~the first~~ 10 min, and ~~maximal depression was~~ observed between 0–30 min ~~following administration~~. ~~Tremors were observed~~ 30 ~~minutes~~ following 1 mg/kg ~~AMB-FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up~~ to 2.5 ~~to 3~~ h ~~at the click through the next webpage highest dose tested (0.5~~ mg/~~kg).~~<br>~~Figure 1.~~ <br>~~There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 (Wiley et al., 2016), and a compound from the present study,~~ 5F-MDMB-PINACA~~, was found to activate midbrain dopamine neurons, but not serotonin neurons~~ (~~Asaoka et al.~~, ~~2016). As previously mentioned, all of the compounds tested in the present study (MDMB~~-PINACA, MDMB-~~CHMICA~~, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA~~) act~~ as ~~agonists at CB1 receptors (Banister et al.~~, ~~2015, 2016; Gamage et al., 2018~~)~~, which suggests these compounds will produce Δ9-THC~~-like effects~~, including~~ abuse liability. Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors in the mic	+	Figure 1. <br>Each training session lasted a maximum of 10 min, and the rats could earn up to 20 food pellets. Thirty minutes prior to the training sessions, rats received an injection of either vehicle or Δ9-THC and were subsequently placed in the behavior-testing chambers, where food (45-mg food pellets; Bio-Serve, Frenchtown, NJ) was available as a reinforcer for every ten responses (FR10) on a designated injection appropriate lever. A houselight was centered over the hopper close to the ceiling and was illuminated only when the levers were active. Each dose range included doses that were without effect to those producing at least 50% depression compared to vehicle control. Twenty-four male Sprague-Dawley rats were obtained from Envigo (Houston, TX). Male ND4 Swiss–Webster mice were obtained from Envigo (Houston, TX) at approximately 8 weeks of age and maintained in the University of North Texas Health Science Center (UNTHSC) animal facility for two weeks prior to testin<br><br><br>Product ions detected at m/z 302, 217, and 145 (B2) confirmed that tert-leucine and indazole moieties remained unchanged, leading to the structure elucidation of a hydroxy-functional group at the 4-position of the butyl side chain by oxidative defluorination. The product ion m/z 336 (loss of methyl ester moiety) further confirmed the presence of dihydroxylated metabolites. The precursor ion, m/z 364 (B14, B5/B6) had a loss of 2 Da from m/z 366 indicated further dehydrogenation of the ester hydrolysis plus monohydroxylated metabolites. The presence of the product ion m/z 320, likely formed from a loss of carbon dioxide, indicated monohydroxylation at the tert-leucine in B8 (m/z 219), butyl side chain in B9 (m/z 145) and indazole moiety in B13 (m/z 161). The precursor ion, m/z 350 showed a loss of 14 Da explaining the hydrolysis of methyl ester from 4F-MDMB-BINACA.<br>Fig. 2. <br>The precursor ion m/z 396 (B10, B12/B15) was 32 Da higher than the parent drug, 4F-MDMB-BINACA, suggesting the addition of two hydroxy groups. All the below explanations for transformations into metabolites are based on the data shown in Fig. Metabolites were identified according to their precursor ions, product ions, and fragmentation patterns (Fig. 1). Traditional in-vivo metabolism studies to generate human metabolites of drugs relied heavily on the use of whole animal model systems, which are expensive, limited by drug administration amount, influenced by species variation and faced by many ethical issues. Eight in-vivo metabolites tentatively identified were mainly products of ester hydrolysis with or without additional dehydrogenation, N-dealkylation, monohydroxylation and oxidative defluorination with further oxidation to butanoic acid.<br>Fig. 1. <br>Monitoring metabolism of synthetic cannabinoid 4F-MDMB-BINACA via high-resolution mass spectrometry assessed in cultured hepatoma cell line, fungus, 5CLADBA liver microsomes and confirmed using urine samples The threshold for fatal overdose of combined use of SCRAs and ethanol can be estimated as a little ng/mL (0.37–4.1 ng/mL according to the reported cases) of SCRA and 1.5–2.5 g/L of ethanol. The reported cases and reviews of the scientific literature suggest a possible synergistic effect between SCRAs and ethanol, because their combined use clearly increases their toxicity. The victim died due to severe necrotizing pancreatitis and acute kidney injury evolving into multi-organ failure 11 days after hospital admission . Studies have found no unequivocal synergistic effect between THC and ethanol at low or moderate ethanol doses [29, 30], but no data on high doses of ethanol are available. Given that THC and ethanol act on the same receptors, data on their simultaneous use may yield important insights in this regard.<br>Fungus C. elegans <br>Concentrations of 4F-MDMB-BINACA in the postmortem blood samples were 2.50 and 2.34 ng/mL, which are in line with published data. Although the lethal dose of 4F-MDMB-BINACA is unknown, its concentration in postmortem blood samples was found to range between 0.10 and 2.90 ng/mL . In SCRA-related cases in which the deceased suffered from heart disease, the SCRA concentration in the postmortem blood was less than 1 ng/mL . Concentrations of SCRAs in postmortem cases cover a wide range ; however, some reports of survival have also been published—even at relatively high blood SCRA concentrations [19, 20<br><br><br>All of the compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al., 2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were [https://cannabinoidsrc4f-adb.com/ 5CLADBA] observed between 0–30 min. Duration of the locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2.5 h following 1 mg/k<br><br>5F-MDMB-PINACA (also known as 5F-ADB, 5F-ADB-PINACA), MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA (also known as FUB-AMB, MMB-FUBINACA) were tested for in vivo cannabinoid-like effects to assess their abuse liabilit

← Nächstältere Version		Version vom 1. Juni 2026, 17:09 Uhr
Zeile 1:		Zeile 1:
−	In general, the locomotor depressant and discriminative stimulus effects [https://cannabinoidsrc4f-adb.com/ click the ~~following web page~~] have been observed at doses that do not produce adverse effects, although tremors were observed upon handling in mice that received JWH-210 (Gatch et al., 2016), and 5F-AMB produced sustained vocalization and convulsions in rats (Gatch et al., 2018). All of the synthetic cannabinoids tested in the present study fully substituted for the discriminative stimulus effects of Δ9-THC. Subsequently, a one-way analysis of variance was conducted on horizontal activity counts for the 30-min period of maximal effect, and planned comparisons were conducted for each dose against the vehicle control using single degree-of-freedom F tests. A two-way analysis of variance, with dose as a between groups factor and time as a within subject factor, was conducted on horizontal activity counts/10 min interval.<br>Michael B Gatch <br>~~Duration of the locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2.5 h following 1 mg/kg.~~ Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at the highest dose tested (0.5 mg/kg). ~~Figure 1 shows average horizontal activity counts/10 min as a function of time (0–4 h) and dose of Δ9-TH~~<br><br>~~<br>To evaluate whether~~ the ~~changes of coordinative functions by CNS damages were due to test substances, rota~~-~~rod test was performed using Rota-rod apparatus~~ (~~Daejong~~, ~~Seoul~~, ~~Korea). The test apparatus for~~ the ~~locomotor activity test~~ was ~~designed~~ to ~~measure locomotor activity automatically using UV system~~ (~~AM 1051~~, ~~Benwick Electronics, Benwick, UK~~) ~~when experimental animals moved in the chamber~~. ~~In both tests~~, ~~a group~~ of ~~mice were treated with negative control~~ (~~vehicle~~, ~~1 mg/kg~~, ~~i.p.)~~, ~~positive control (methamphetamine~~, ~~1 mg/kg, i.p.~~)~~, or one of the three doses of test substances~~ (0.1, 1, ~~5 mg/kg~~, ~~i.p.~~) once every other day for 10 day<br><br><br>Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect. Previous studies have demonstrated that these compounds ~~have chemical structures similar to synthetic cannabinoids known to have substantial~~ abuse liability ~~and act at the CB1 receptor~~. Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors in the mice. AMB-FUBINACA has been implicated in severe adverse effects in recreational users (Adams et al., 2017; Hamilton et al., 2017), which suggests that the range between behaviorally active and toxic doses of AMB-FUBINACA is narrow. Following that line of reasoning, it should also be noted that some of the more recent compounds produced non-linear dose-effect curves and one compound produced an inverted U-shaped dose-effect, such that intermediate dose fully substituted, but higher doses did not (Gatch and Forster, 2018). All of the compounds identified as available on the recreational market and submitted to our laboratory by the US Drug Enforcement Agency for testing have fully substituted at some dose (Gatch and Forster 2014, 2015, 2016, 2018); however; it is important to note that not all structural congeners are active (Wiley et al., 2012<br><br><br>LC separates the urine or blood sample and QTOF-MS provides high-resolution and accurate mass measurements for precise identification and structural elucidation of compounds. The LC-QTOF-MS method offers a more comprehensive and sensitive approach for drug detection, covering hundreds of recreational drugs, including NPS. Besides increasing the temperature to enlarge the drug aerolisation and bioavailability, one can elevate the flow rate of air through the e-cigarette and/or add a diluent . Of all e-cigarette users registered at this forum, 7.8 % vaped SCRAs . About 15 % of individuals registered at forums for drug users such as erowid.org who vaped cannabis have also vaped SRCAs. SCRAs belong, together with synthetic opioids, cathinones, amphetamines and hallucinogens to the new psychoactive substances (NPS) that are currently developed at high speed.<br>Data availabili<br><br>In case of cannabis or Δ9-tetrahydrocannabinol, there are many previous studies regarding with their dependence potential and neurotoxicity (Cororan, et al., 1974; Harris, et al., 1974; Leite and Culini, 1974; Hutcheson, et al., 1998<br><br>Thirty minutes prior to the training sessions, rats received an injection of either vehicle or Δ9-THC and were subsequently placed in the behavior-testing chambers, where food (45-mg food pellets; Bio-Serve, Frenchtown, NJ) was available as a reinforcer for every ten responses (FR10) on a designated injection appropriate leve	+	All of the compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al., 2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were click through the next webpage observed between 0–30 min. Duration of the locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2.5 h following 1 mg/k<br><br>One recent study has looked at other mechanisms of action in some of the older synthetic cannabinoids and reported that some produced varying amounts of activity at sites which are related to cardiotoxicity and heart disease (Wiley et al., 2016<br><br><br>Although there were reports on the metabolism of 4F-MDMB-BINACA using in-vivo and various in-vitro models, studies were either conducted using small in-vivo sample size such as 1 to 4 samples [5, 29] or in closed environments such as forensic psychiatric wards and prisons . The hepatic cell line HepG2 is often used as an initial screen as it is known to produce high reproducibility results with relatively stable enzyme concentration, although they are limited by the low-level expression of several metabolizing enzymes, including the cytochrome P450 (CYP) class of proteins [17, 18]. In-vitro metabolism studies are generally used to complement these data using perfused organs, tissue or cell cultures and microsomal preparations amongst which pooled human liver microsomes (HLM) have been frequently used to elucidate metabolism of SCBs [12,13,14,15,16]. Since most SCBs are found extensively in metabolized forms in urine, the identification of metabolites is of vital importance for forensic and clinical toxicologists. Identifying SCB intake and its correlating specific adverse effects require rapid elucidation of these SCBs. The proliferation of SCBs has become a global challenge as new compounds are rapidly introduced into the illegal drug market to evade existing drug law<br><br>In general, the locomotor depressant and discriminative stimulus effects have been observed at doses that do not produce adverse effects, although tremors were observed upon handling in mice that received JWH-210 (Gatch et al., 2016), and 5F-AMB produced sustained vocalization and convulsions in rats (Gatch et al., 2018<br><br><br>Taken together these data further confirmed the structure elucidation of B16. The precursor ion m/z 276 (B1) detected, which was 74 Da lower than that for the 4F-MDMB-BINACA ester hydrolysis metabolite (B22), indicated N-dealkylation of B22. The precursor ion m/z 348 and product ion detected at m/z 217 (B2) identified was 2 Da less than the 4F-MDMB-BINACA ester hydrolysis metabolite (B22), indicating oxidative defluorination (loss of fluorine with addition of hydroxy [https://cannabinoidsrc4f-adb.com/ click through the next webpage] group<br><br><br>The same procedure was then applied to the mice once every day for 5 days. It was considered as coordination disturbance when mice fell from the test apparatus within 2 min. Mice that remained their position on the running apparatus at 10 rpm for at least 2 min were selected for further evaluation.<br>Table of Conten<br><br><br>When clinical presentation and/or initial DOA testing results are inconclusive, additional testing with LC-QTOF-MS can be valuable and is recommended. SCRAs and other NPS may not be detected by point-of-care DOA tests. In this case, the point-of-care DOA urine screening was not able to detect the synthetic cannabinoid ADB-BUTINAC<br><br><br>Similarly, precursor ion identified at m/z 380 (B19/B21, B23/B25) was 16 Da higher than the 4F-MDMB-BINACA, indicating monohydroxylation at the butyl side chain (B19/B21) and indazole (B23/B25) moieties with product ions m/z 145 and 161, respectively. Metabolites identified at m/z 366 (B8, B9, B13), which was 16 Da higher than the 4F-MDMB-BINACA ester hydrolysis metabolite (B22), confirmed monohydroxylation upon ester hydrolysis. Death involving these drugs have been reported [5,6,7,8,9], and this raises public health and social concerns. Due to their similar physiological effects to the principal psychoactive component of cannabis, Δ9-tetrahydrocannabinol (THC), SCBs are gaining popularity and are often abused as recreational drugs. The fact that similar 4F-MDMB-BINACA and ethanol concentrations were detected in the postmortem blood samples of both victims suggests that both substances played a role in the fatal outcom<br><br>4. Drugs <br>In general, the locomotor depressant and discriminative stimulus effects have been observed at doses that do not produce adverse effects, although tremors were observed upon handling in mice that received JWH-210 (Gatch et al., 2016), and 5F-AMB produced sustained vocalization and convulsions in rats (Gatch et al., 2018). All of the synthetic cannabinoids tested in the present study fully substituted for the discriminative stimulus effects of Δ9-THC. Subsequently, a one-way analysis of variance was conducted on horizontal activity counts for the 30-min period of maximal effect, and planned comparisons were conducted for each dose against the vehicle control using single degree-of-freedom F tests. A two-way analysis of variance, with dose as a between groups factor and time as a within subject factor, was conducted on horizontal activity counts/10 min interval. Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at the CB1 receptor.<br>Michael B Gatch <br>Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at the click through the next webpage highest dose tested (0.5 mg/kg).<br>Figure 1. <br>There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 (Wiley et al., 2016), and a compound from the present study, 5F-MDMB-PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016). As previously mentioned, all of the compounds tested in the present study (MDMB-PINACA, MDMB-CHMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA) act as agonists at CB1 receptors (Banister et al., 2015, 2016; Gamage et al., 2018), which suggests these compounds will produce Δ9-THC-like effects, including abuse liability. Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors in the mic

← Nächstältere Version		Version vom 30. Mai 2026, 18:51 Uhr
Zeile 1:		Zeile 1:
−	~~The findings produce an apparent paradox~~, ~~since CPP~~ and ~~self~~-~~administration predict with high reliability~~ the ~~likelihood~~ that ~~a compound will be abused by humans, and cannabinoids are well-known to~~ produce ~~active drug-seeking in human<br><br><br>Although there were reports on the metabolism of 4F-MDMB-BINACA using in-vivo and various in-vitro models~~, ~~studies~~ were ~~either conducted using small~~ in-~~vivo sample size such as 1 to 4 samples [5, 29] or in closed environments such as forensic psychiatric wards and prisons~~ . The hepatic cell line HepG2 is often used as an initial screen as it is known to produce high reproducibility results with relatively stable enzyme concentration, although they are limited by the low-level expression of several metabolizing enzymes, ~~including the cytochrome P450 (CYP~~) ~~class of proteins [17~~, ~~18]. In~~-~~vitro metabolism studies are generally used to complement these data using perfused organs, tissue or cell cultures~~ and ~~microsomal preparations amongst which pooled human liver microsomes~~ (~~HLM~~) ~~have been frequently used to elucidate metabolism~~ of ~~SCBs [12,13,14,15,16]. Since most SCBs are found extensively~~ in ~~metabolized forms in urine,~~ the ~~identification~~ of ~~metabolites is~~ of ~~vital importance~~ for ~~forensic~~ and ~~clinical toxicologists. Identifying SCB intake and its correlating specific adverse effects require rapid elucidation~~ of ~~these SCBs~~. ~~The proliferation~~ of ~~SCBs has become~~ a ~~global challenge~~ as ~~new compounds are rapidly introduced into the illegal drug market to evade existing drug laws~~.<br>~~Fig.~~ <br>~~<br><br>Thirty minutes prior~~ to the ~~training sessions~~, ~~rats received an injection of either vehicle or Δ9-THC~~ and were ~~subsequently placed in the behavior-testing chambers, where food (45-~~mg ~~food pellets; Bio~~-~~Serve, Frenchtown, NJ) was available as a reinforcer for every ten responses~~ (~~FR10~~) ~~on a designated injection appropriate lever~~. ~~A houselight was centered over~~ the ~~hopper close to the ceiling~~ and was ~~illuminated only when the levers were active~~. ~~Each dose range included doses that were without effect~~ to ~~those producing~~ at ~~least 50% depression compared to vehicle control. Twenty-four male Sprague-Dawley rats were obtained from Envigo~~ (~~Houston, TX)~~. ~~[https:~~/~~/cannabinoidsrc4f-adb~~.~~com~~/ ~~JWH-210 powder] Male ND4 Swiss–Webster mice were obtained from Envigo~~ (~~Houston, TX~~) ~~at approximately 8 weeks of age~~ and ~~maintained in the University~~ of ~~North Texas Health Science Center (UNTHSC) animal facility for two weeks prior to testin~~<br><br>~~4. Drugs~~ <br>~~Short~~-~~onset~~, ~~short-acting compounds have a greater abuse liability~~, ~~and long-acting compounds pose problems of long-acting adverse effects and interactions with other drugs~~. The ~~duration of action of~~ the ~~synthetic cannabinoids tested~~ using the ~~8-h protocol have varied widely~~, ~~with some producing~~ a ~~duration~~ of ~~action no longer than~~ 1 h, ~~others producing a duration of action between 1–2 h~~, ~~and others lasting more than 2 h~~. ~~There seems to be a trend of newer synthetic cannabinoids being more potent than earlier compounds~~. ~~All~~ of the ~~compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids~~ (~~see review by Wiley et al~~., ~~2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of~~ 1~~.33~~ mg/kg ~~were observed within~~ 10 ~~min following administration and peak depressant effects were observed between 0–30 min.<br>Michael B Gat~~<br><br><br>Tremors were observed ~~in mice 30 minutes~~ following ~~1 mg/kg~~ AMB-FUBINACA ~~in the present study. Pretreatment times and dose ranges for~~ the drug discrimination ~~assay were selected based on~~ the ~~time of peak depression in the locomotor activity assay in mice. Average potency of the discriminative stimulus effects of early compounds~~ was 0.~~81±0.17~~ mg/kg (~~Gatch~~ et al., ~~2014), whereas the potency of a recent set was 0.09±0.03 mg/kg (Gatch~~ et al., ~~2018~~), and ~~the potency~~ of ~~the current set~~ is 0.~~05±0.01 mg/kg. Short~~-~~onset, short~~-~~acting compounds have a greater abuse liability,~~ and ~~long~~-~~acting compounds pose problems of long~~-~~acting adverse effects~~ and ~~interactions with other drugs~~. ~~The duration of action~~ of the ~~synthetic cannabinoids tested using~~ the ~~8-h protocol~~ have ~~varied widely~~, ~~with some producing a duration of action no longer than 1 h~~, ~~others producing a duration of action between 1–2 h~~, ~~and others lasting more than 2 h~~. ~~There seems to be a trend of newer synthetic cannabinoids being more potent than earlier compound~~<br><br><br>~~Demographic and clinical features are recorded and~~ blood and~~/or urine samples analysed using~~ high-resolution accurate mass ~~liquid chromatography-mass spectrometry~~. The ~~authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Second, we could not JWH~~-~~210 powder retrieve further detailed information about the e~~-~~cigarette that was used by the patient such as the label or the region~~ of ~~origin. Whether a~~ recreational ~~drug can be administered via vaping~~, ~~depends on whether~~ the drug ~~becomes volatile under~~ the ~~evaporation temperature~~ of the e-cigarette. Of ~~these samples~~, ~~22 contained one or more~~ SCRAs, ~~THC was only detected in 11 samples~~, ~~only one contained cannabidiol~~ and ~~6 contained a mixture~~ of ~~THC~~ and ~~cannabidiol~~. ~~There is difficulty in finding the right information about the NPS~~, ~~defining their potency~~ and ~~confirmation of their existence in e-liquids or urine samples~~.<br>~~Data availabili~~	+	In general, the locomotor depressant and discriminative stimulus effects [https://cannabinoidsrc4f-adb.com/ click the following web page] have been observed at doses that do not produce adverse effects, although tremors were observed upon handling in mice that received JWH-210 (Gatch et al., 2016), and 5F-AMB produced sustained vocalization and convulsions in rats (Gatch et al., 2018). All of the synthetic cannabinoids tested in the present study fully substituted for the discriminative stimulus effects of Δ9-THC. Subsequently, a one-way analysis of variance was conducted on horizontal activity counts for the 30-min period of maximal effect, and planned comparisons were conducted for each dose against the vehicle control using single degree-of-freedom F tests. A two-way analysis of variance, with dose as a between groups factor and time as a within subject factor, was conducted on horizontal activity counts/10 min interval.<br>Michael B Gatch <br>Duration of the locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2.5 h following 1 mg/kg. Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at the highest dose tested (0.5 mg/kg). Figure 1 shows average horizontal activity counts/10 min as a function of time (0–4 h) and dose of Δ9-TH<br><br><br>To evaluate whether the changes of coordinative functions by CNS damages were due to test substances, rota-rod test was performed using Rota-rod apparatus (Daejong, Seoul, Korea). The test apparatus for the locomotor activity test was designed to measure locomotor activity automatically using UV system (AM 1051, Benwick Electronics, Benwick, UK) when experimental animals moved in the chamber. In both tests, a group of mice were treated with negative control (vehicle, 1 mg/kg, i.p.), positive control (methamphetamine, 1 mg/kg, i.p.), or one of the three doses of test substances (0.1, 1, 5 mg/kg, i.p.) once every other day for 10 day<br><br><br>Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at the CB1 receptor. Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors in the mice. AMB-FUBINACA has been implicated in severe adverse effects in recreational users (Adams et al., 2017; Hamilton et al., 2017), which suggests that the range between behaviorally active and toxic doses of AMB-FUBINACA is narrow. Following that line of reasoning, it should also be noted that some of the more recent compounds produced non-linear dose-effect curves and one compound produced an inverted U-shaped dose-effect, such that intermediate dose fully substituted, but higher doses did not (Gatch and Forster, 2018). All of the compounds identified as available on the recreational market and submitted to our laboratory by the US Drug Enforcement Agency for testing have fully substituted at some dose (Gatch and Forster 2014, 2015, 2016, 2018); however; it is important to note that not all structural congeners are active (Wiley et al., 2012<br><br><br>LC separates the urine or blood sample and QTOF-MS provides high-resolution and accurate mass measurements for precise identification and structural elucidation of compounds. The LC-QTOF-MS method offers a more comprehensive and sensitive approach for drug detection, covering hundreds of recreational drugs, including NPS. Besides increasing the temperature to enlarge the drug aerolisation and bioavailability, one can elevate the flow rate of air through the e-cigarette and/or add a diluent . Of all e-cigarette users registered at this forum, 7.8 % vaped SCRAs . About 15 % of individuals registered at forums for drug users such as erowid.org who vaped cannabis have also vaped SRCAs. SCRAs belong, together with synthetic opioids, cathinones, amphetamines and hallucinogens to the new psychoactive substances (NPS) that are currently developed at high speed.<br>Data availabili<br><br>In case of cannabis or Δ9-tetrahydrocannabinol, there are many previous studies regarding with their dependence potential and neurotoxicity (Cororan, et al., 1974; Harris, et al., 1974; Leite and Culini, 1974; Hutcheson, et al., 1998<br><br>Thirty minutes prior to the training sessions, rats received an injection of either vehicle or Δ9-THC and were subsequently placed in the behavior-testing chambers, where food (45-mg food pellets; Bio-Serve, Frenchtown, NJ) was available as a reinforcer for every ten responses (FR10) on a designated injection appropriate leve

← Nächstältere Version		Version vom 30. Mai 2026, 18:46 Uhr
Zeile 1:		Zeile 1:
−	~~Such decrease remained 2 hr after~~ the ~~administration (Table 4). In locomotor activity~~, ~~methamphetamine treated group showed approximately 4.2 times increase compared~~ to ~~the negative control treated group. Change of body weight following the treatments with JWH~~-~~081 and JWH-210~~ in ~~mic~~<br><br><br>LC-~~QTOF~~-~~MS represents a significant advancement~~ in ~~the field of drug detection, offering higher sensitivity, specificity,~~ and ~~a broader spectrum of detectable substances. Despite all negative results~~ in ~~the point~~-~~of-care test for recreational drugs~~, ~~the liquid chromatography~~-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) analysis showed that the liquid of the e-cigarette contained ADB-BUTINACA, a synthetic cannabinoid. We report a 27-year-old man who was admitted to ~~the emergency room because of sudden 5CL ADBA powder headache~~, ~~nausea, vertigo, red eyes~~ and ~~palpitations~~. ~~Synthetic cannabinoids are gaining popularity globally and detection~~ is ~~not commonly availabl<br><br><br>A 30-min period, beginning when maximal depression of locomotor activity first appeared~~ as ~~a function of dose~~, ~~was used for analysis of dose~~-~~response data and calculation~~ of ~~ED50 values. During test sessions~~, ~~both levers were active~~, ~~such that ten consecutive responses on either lever led to [https://cannabinoidsrc4f-adb.com/ 5CL ADBA powder~~] ~~reinforcement~~. ~~The substitution tests occurred only if the rats had achieved 85% injection~~-~~appropriate responding on the two prior training sessions.<br>The locomotor activity assay was~~ used to ~~identify approximate time courses~~ and ~~dose ranges of psychoactive effects,~~ which ~~is useful for identifying parameters for drug discrimination experiments and are also predictive of the time course of the psychoactive effects in~~ human ~~users. The purpose of the present study was~~ to ~~assess the abuse liability~~ of ~~5F-MDMB-PINACA~~, ~~MDMB-CHIMICA~~, ~~MDMB-FUBINACA~~, ~~ADB-FUBINACA~~, ~~and AMB-FUBINACA~~. Since ~~there is currently no robust measure of~~ the ~~reinforcing/rewarding effects~~ of ~~cannabinoids, drug discrimination~~ is ~~currently the best model~~ for ~~assessing abuse liability~~ of ~~cannabinoids~~. The ~~findings produce an apparent paradox, since CPP and self-administration predict with high reliability the likelihood that~~ a ~~compound will be abused by humans, and cannabinoids~~ are ~~well-known~~ to ~~produce active~~ drug~~-seeking in human<br>~~<br>The chemical structures of the recent synthetic cannabinoids are unlike that of Δ9-THC, but are largely based on the structure of older synthetic cannabinoids that are known to have substantial abuse liability (Fig. 1<br><br><br>~~The current study indicates that~~ the ~~test compounds produce locomotor depression similar to that~~ of Δ9-THC, and ~~fully substitute for~~ the ~~discriminative stimulus effects of Δ9~~-~~THC. In summary~~, ~~these 5F~~-~~MDMB~~-~~PINACA~~, ~~MDMB-CHIMICA~~, ~~MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA have similar abuse liability~~ as ~~Δ9-tetrahydrocannabinol and should be controlled in~~ a ~~similar fashion~~. ~~Much of~~ the ~~in vivo 5CL ADBA powder testing of~~ the ~~synthetic cannabinoid compounds have been pre-clinical studies focused on their cannabinoid-like effects or like~~ the ~~present study, focused on their abuse liability~~. ~~There is indication~~ that at least ~~some of the first~~-~~generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2~~ (~~Wiley et al.~~, ~~2016~~)~~, and a compound from the present study, 5F~~-~~MDMB~~-~~PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons~~ (~~Asaoka et al.~~, ~~2016<br><br>Metabolic Profile~~ of ~~Synthetic Cannabinoids 5F-PB-22, PB-22, XLR-11~~ and ~~UR-144 by Cunninghamella elegans <br>This might be due to the low activity of numerous metabolizing enzymes resulting~~ in ~~lower drug biotransformation . HepG2 model detected~~ the ~~major ester hydrolysis metabolite~~ of ~~4F-MDMB-BINACA in abundance but the rest of the metabolites were found in a small amount. Elegans and HLM models detected all of the in-vivo metabolites~~ (~~100%~~)~~, whilst HepG2 cells detected 7 out of the 8 in-vivo metabolites (87.5%). Hence, structural elucidation could not be confirmed unless a reference standard is made availabl~~<br><br>4. Drugs <br>Short-onset, short-acting compounds have a greater abuse liability, and long-acting compounds pose problems of long-acting adverse effects and interactions with other drugs. The duration of action of the synthetic cannabinoids tested using the 8-h protocol have varied widely, with some producing a duration of action no longer than 1 h, others producing a duration of action between 1–2 h, and others lasting more than 2 h. There seems to be a trend of newer synthetic cannabinoids being more potent than earlier compounds. All of the compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al., 2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were observed between 0–30 min.<br>Michael B Gat	+	The findings produce an apparent paradox, since CPP and self-administration predict with high reliability the likelihood that a compound will be abused by humans, and cannabinoids are well-known to produce active drug-seeking in human<br><br><br>Although there were reports on the metabolism of 4F-MDMB-BINACA using in-vivo and various in-vitro models, studies were either conducted using small in-vivo sample size such as 1 to 4 samples [5, 29] or in closed environments such as forensic psychiatric wards and prisons . The hepatic cell line HepG2 is often used as an initial screen as it is known to produce high reproducibility results with relatively stable enzyme concentration, although they are limited by the low-level expression of several metabolizing enzymes, including the cytochrome P450 (CYP) class of proteins [17, 18]. In-vitro metabolism studies are generally used to complement these data using perfused organs, tissue or cell cultures and microsomal preparations amongst which pooled human liver microsomes (HLM) have been frequently used to elucidate metabolism of SCBs [12,13,14,15,16]. Since most SCBs are found extensively in metabolized forms in urine, the identification of metabolites is of vital importance for forensic and clinical toxicologists. Identifying SCB intake and its correlating specific adverse effects require rapid elucidation of these SCBs. The proliferation of SCBs has become a global challenge as new compounds are rapidly introduced into the illegal drug market to evade existing drug laws.<br>Fig. <br><br><br>Thirty minutes prior to the training sessions, rats received an injection of either vehicle or Δ9-THC and were subsequently placed in the behavior-testing chambers, where food (45-mg food pellets; Bio-Serve, Frenchtown, NJ) was available as a reinforcer for every ten responses (FR10) on a designated injection appropriate lever. A houselight was centered over the hopper close to the ceiling and was illuminated only when the levers were active. Each dose range included doses that were without effect to those producing at least 50% depression compared to vehicle control. Twenty-four male Sprague-Dawley rats were obtained from Envigo (Houston, TX). [https://cannabinoidsrc4f-adb.com/ JWH-210 powder] Male ND4 Swiss–Webster mice were obtained from Envigo (Houston, TX) at approximately 8 weeks of age and maintained in the University of North Texas Health Science Center (UNTHSC) animal facility for two weeks prior to testin<br><br>4. Drugs <br>Short-onset, short-acting compounds have a greater abuse liability, and long-acting compounds pose problems of long-acting adverse effects and interactions with other drugs. The duration of action of the synthetic cannabinoids tested using the 8-h protocol have varied widely, with some producing a duration of action no longer than 1 h, others producing a duration of action between 1–2 h, and others lasting more than 2 h. There seems to be a trend of newer synthetic cannabinoids being more potent than earlier compounds. All of the compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al., 2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were observed between 0–30 min.<br>Michael B Gat<br><br><br>Tremors were observed in mice 30 minutes following 1 mg/kg AMB-FUBINACA in the present study. Pretreatment times and dose ranges for the drug discrimination assay were selected based on the time of peak depression in the locomotor activity assay in mice. Average potency of the discriminative stimulus effects of early compounds was 0.81±0.17 mg/kg (Gatch et al., 2014), whereas the potency of a recent set was 0.09±0.03 mg/kg (Gatch et al., 2018), and the potency of the current set is 0.05±0.01 mg/kg. Short-onset, short-acting compounds have a greater abuse liability, and long-acting compounds pose problems of long-acting adverse effects and interactions with other drugs. The duration of action of the synthetic cannabinoids tested using the 8-h protocol have varied widely, with some producing a duration of action no longer than 1 h, others producing a duration of action between 1–2 h, and others lasting more than 2 h. There seems to be a trend of newer synthetic cannabinoids being more potent than earlier compound<br><br><br>Demographic and clinical features are recorded and blood and/or urine samples analysed using high-resolution accurate mass liquid chromatography-mass spectrometry. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Second, we could not JWH-210 powder retrieve further detailed information about the e-cigarette that was used by the patient such as the label or the region of origin. Whether a recreational drug can be administered via vaping, depends on whether the drug becomes volatile under the evaporation temperature of the e-cigarette. Of these samples, 22 contained one or more SCRAs, THC was only detected in 11 samples, only one contained cannabidiol and 6 contained a mixture of THC and cannabidiol. There is difficulty in finding the right information about the NPS, defining their potency and confirmation of their existence in e-liquids or urine samples.<br>Data availabili